Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergoogle.com
Google Alert - HER2-ADC
Get the latest updates from Google Alert - HER2-ADC directly as they happen.
Follow now 122 followers
Latest posts
Last updated about 5 hours ago
Personalizing Frontline ADC Selection in Metastatic Triple-Negative Breast Cancer
about 9 hours ago
... HER2- Metastatic Breast Cancer | Iowa Oncology Society. Aditya Bardia, MD...
Callio Therapeutics Names Zachary Hornby As CEO To Advance Dual-Payload Cancer ...
1 day ago
Its lead clinical candidate, CLIO-8221, is a HER2-targeted dual-payload ADC delivering a...
USP9X: A Potential New Way to Sensitize Tumors to ADC Therapy | Breast Cancers Today
2 days ago
Dr. Polyak explains how CRISPR screens identified USP9X as a new therapeutic...
HER2+ Directed Therapies Market Outlook 2034: Growth Trends, - openPR.com
1 day ago
... HER2-positive biliary tract cancer. Disitamab vedotin: Pfizer/RemeGen - a HER2-targeted ADC...
Intracellular Nanopharmacology of Trastuzumab Deruxtecan Reveals Lysosome-Centered ...
2 days ago
Abstract. Trastuzumab-deruxtecan (T-DXd) is a clinically effective antibody–drug conjugate (ADC) with activity...
Theranostic Frontiers in HER2-Positive Breast Cancer: Nanomedicine Meets Morphology
2 days ago
Antibody–Drug Conjugates (ADCs), Targeted anticancer therapeutics composed of a monoclonal antibody linked...
United States Antibody-Drug Conjugates (ADC) Market 2026 | - openPR.com
2 days ago
HER2 antibodies dominate with 43% share, driven by the established use of...
TKD Mutation Status and CNS Data Guide Frontline Sequencing in HER2-Mutant NSCLC
3 days ago
... ADC using a more potent topoisomerase-1 payload than other ADCs. This...
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer | Markets Insider
3 days ago
... ADCs and deliver the next generation of ADC medicines for patients...
Metastatic HER2-Positive Breast Cancer Market To Grow At 8.3% CAGR Through 2036 ... - Mena FN
4 days ago
HER2-targeted therapies, including HERCEPTIN, PERJETA, KADCYLA, ENHERTU, TUKYSA, and PHESGO, continue to...
Disitamab vedotin shows phase 3 benefit in HER2-positive breast cancer liver metastases
4 days ago
... ADC. These molecules are engineered to combine the targeting specificity of...
New Treatments for Breast Cancer
5 days ago
The agency also approved two new indications for Enhertu (trastuzumab deruxtecan), an...